scholarly article | Q13442814 |
P50 | author | Alzheimer's Disease Neuroimaging Initiative | Q4738819 |
Jordi Clarimón | Q38327609 | ||
Daniel A. Alcolea | Q41362963 | ||
María Carmona-Iragui | Q43551870 | ||
Eduard Vilaplana | Q57002404 | ||
P2093 | author name string | Alberto Lleó | |
Rafael Blesa | |||
Juan Fortea | |||
Isabel Sala | |||
María-Belén Sánchez-Saudinos | |||
Sofía Antón-Aguirre | |||
Estrella Morenas | |||
Jordi Pegueroles | |||
Santiago Medrano | |||
Sofía González | |||
P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
Measuring the thickness of the human cerebral cortex from magnetic resonance images | Q29615080 | ||
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 | ||
Amyloid burden and neural function in people at risk for Alzheimer's Disease | Q33599047 | ||
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease | Q33699415 | ||
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease | Q33709263 | ||
Brain changes in older adults at very low risk for Alzheimer's disease | Q33729050 | ||
Tau is essential to beta -amyloid-induced neurotoxicity | Q34029253 | ||
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model | Q34162478 | ||
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. | Q34514638 | ||
Amyloid-β associated cortical thinning in clinically normal elderly | Q35053524 | ||
Amyloid-β associated volume loss occurs only in the presence of phospho-tau | Q36010484 | ||
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau | Q36177140 | ||
Brain injury biomarkers are not dependent on β-amyloid in normal elderly | Q36863815 | ||
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals | Q37090083 | ||
Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons | Q37221892 | ||
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | Q37227424 | ||
Beta-amyloid burden is not associated with rates of brain atrophy | Q37326537 | ||
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease | Q37332710 | ||
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly | Q37391300 | ||
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study | Q37524511 | ||
Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. | Q37604297 | ||
Tau pathology and neurodegeneration | Q38107632 | ||
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. | Q39173722 | ||
Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP x PS1 mice using MRI. | Q39877007 | ||
Frequency of stages of Alzheimer-related lesions in different age categories | Q42445469 | ||
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. | Q43738741 | ||
Larger temporal volume in elderly with high versus low beta-amyloid deposition | Q43965311 | ||
Apolipoprotein E ε4-related thickening of the cerebral cortex modulates selective attention | Q44110544 | ||
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
Synaptic contact number and size in stratum radiatum CA1 of APP/PS1DeltaE9 transgenic mice. | Q47242407 | ||
Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. | Q48341077 | ||
Phases of A beta-deposition in the human brain and its relevance for the development of AD. | Q48567985 | ||
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. | Q51011713 | ||
P433 | issue | 2 | |
P921 | main subject | Alzheimer's disease | Q11081 |
cerebrospinal fluid | Q54196 | ||
biomarker | Q864574 | ||
P304 | page(s) | 223-230 | |
P577 | publication date | 2014-06-13 | |
P1433 | published in | Annals of Neurology | Q564414 |
P1476 | title | Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease | |
P478 | volume | 76 |